secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001193125-22-270962
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silverback amends merger agreement with ARS Pharma; raises net cash ceiling to $265M
--------------------------------------------------------------------------------

- Parent Net Cash condition revised: must be between $210M and $265M, increased from $255M ceiling.
- If net cash exceeds $265M, Silverback may declare a dividend for excess amount to satisfy closing condition.
- Parent Valuation definition updated: adds up to $25M of cash above $240M to equity value.
- Amendment signed Oct 25, 2022; merger still subject to stockholder approval and other conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522270962/0001193125-22-270962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522270962/d416966d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-270962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer